Does long-term chloramphenicol cause anaemia in Malawi?

Area of Science:

• Paediatrics
• Infectious Diseases
• Hematology

Background:

• Current pediatric practice often limits chloramphenicol treatment to two weeks due to concerns about potential anemia.
• This limitation is not supported by existing research or animal studies, suggesting a need for re-evaluation.

Purpose of the Study:

• To investigate the safety and efficacy of a six-week course of chloramphenicol in treating pediatric septic arthritis.
• To assess the impact of prolonged chloramphenicol treatment on hemoglobin levels and anemia in children.

Main Methods:

• A cohort of 146 children with septic arthritis received a six-week course of chloramphenicol.
• Clinical improvement was monitored, and hemoglobin levels were assessed at presentation, during treatment, and at six months post-treatment.

Main Results:

• All 146 children demonstrated clinical improvement following the six-week chloramphenicol treatment.
• Children presenting with anemia showed rapid improvement concurrent with infection resolution.
• Hemoglobin levels normalized and were maintained at six months post-treatment (mean Hb 10.57 SD 1.86).

Conclusions:

• A six-week course of chloramphenicol is clinically effective for pediatric septic arthritis.
• Prolonged chloramphenicol administration does not exacerbate anemia and can be safely used in this patient population.